Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B
Melissa Leichter, Rare Disease Executive, Novo Nordisk, shared a proud announcement post on LinkedIn:
”Today marks an exciting step forward for the hemophilia community. The FDA has approved our new subcutaneous prophylactic treatment for patients aged 12 and older living with hemophilia A or B.
This approval builds on our earlier indication for people living with hemophilia with inhibitors and reflects our continued commitment to expanding access and reimagining care across the hemophilia landscape.
Behind this milestone is a team of passionate, driven individuals who work tirelessly to bring innovative solutions to life. I am incredibly proud to be part of this journey—one that’s focused on delivering better options and more control for people navigating life with hemophilia. Thank you to the entire team who has contributed to this great achievement. Your dedication makes a real difference.”
Melissa Leichter proudly shares news on FDA Approvement for Alhemo.
Latest news in the field of Hemophilia Management featured in Hemostasis Today.
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
-
Aug 26, 2026, 13:54Giuseppe Biondi Zoccai: Congratulations to the Next Editor-in-Chief of the EHJ
-
Aug 26, 2026, 13:25Omar Adwan: Abnormal Nuclear Morphology of Neutrophil
-
Aug 26, 2026, 13:05Preventing Thrombosis with WTDay26
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?